TenaRx

TenaRx is a San Diego-based biotechnology company and a majority-owned subsidiary of Biosplice Therapeutics. The company is focused on building a new therapeutic class around the selective inhibition of the CLK (Cdc2-like kinase) and DYRK (Dual-specificity tyrosine-phosphorylation-regulated kinase) families. These kinases are central regulators of cell fate, immune signaling, metabolism, and neurodevelopment, representing high-value nodes for drug development. TenaRx is currently advancing a pipeline of small-molecule programs targeting oncology, metabolic diseases such as diabetes, and neurodegenerative disorders. By leveraging precision kinase-targeted innovation, the company aims to deliver disease-modifying therapies for patients with significant unmet medical needs.